TORONTO - Laurie Miller, a 59-year-old heart transplant patient exposed to measles in Stratford, Ont., says her story speaks to the risks people who are immunocompromised face during an outbreak.

Serkan Oray from UCB shares why the autoinjector pen format is booming, the importance of a patient-centric design, and how ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesCompany aims to accelerate access to much-needed biosimilar to reference ...

The data showed no clinically meaningful differences between the biosimilar and the reference product in terms of safety, efficacy, immunogenicity and ...

The U.S. Food and Drug Administration (U.S. FDA) has approved Biocon Biologics’ Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous use. JOBEVNE, a recombinant humanized ...

Biocon Biologics, the biosimilar arm of Biocon has expanded its oncology portfolio with the USFDA approval of Jobevne, a cancer treatment drug. Jobevne is a biosimilar version of Bevacizumab ...

Kepler Capital analyst Justine Telliez maintained a Hold rating on GenSight Biologics SA (G49N – Research Report) on April 8 and set a price target of €0.40. The company’s shares closed last ...

The approval of JOBEVNE expands Biocon Biologics' biosimilar oncology portfolio in the United States, which also includes OGIVRI (Trastuzumab-dkst) and FULPHILA (Pegfilgrastim-jmdb). The Company ...

Aurobindo Pharma's Bone Treatment Drug Shows Promise in Tests Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has announced successful trial results for its new bone treatment medicine. The drug, ...

Biocon Biologics has received the Food and Drug Administration’s green light for Jobevne (bevacizumab-nwgd), a biosimilar bevacizumab for intravenous use. Jobevne, which is a recombinant ...

BRIDGEWATER, N.J. and BENGALURU, India, April 10, 2025 /PRNewswire/ --Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and ...